No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Dongyao Pharmaceutical - B (01875) revenue in the first three quarters increased by 49% year-on-year to 0.809 billion yuan.
Dongyao Pharmaceuticals - B (01875) announced that as of the nine months ended September 30, 2024, the Group's revenue...
Express News | TOT BIOPHARM International 9M Revenue RMB 809.021 Million
TOT BIOPHARM-B: INTERIM REPORT 2024
Dongyao Pharmaceuticals (1875.HK): CDMO project pool expands steadily, combining certainty and growth.
On August 7th, Hang Seng Index Company stated in an article that the biotech sector has shown signs of improvement recently, benefiting from policy support and a continuous inflow of funds over the past three months. With more policies being implemented, the Hang Seng Hong Kong-listed Biotech Index has outperformed the market since July. Clearly, the positive changes revealed in Hang Seng's article provide investors with a new perspective, which may also indicate a new turning point for the entire healthcare sector. In the current situation where the entire sector is still undervalued, as pharmaceutical companies enter the earnings season in the near future, it also brings a window of opportunity for the market to assess company value and predict future development. Recently, the interim report of the company was released.
